This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Park, I. H.
Right arrow Articles by Shin, J.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Park, I. H.
Right arrow Articles by Shin, J.-S.

 Previous Article  |  Next Article 

Infection and Immunity, October 2005, p. 6399-6406, Vol. 73, No. 10
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.10.6399-6406.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Anti-Idiotypic Antibody as a Potential Candidate Vaccine for Neisseria meningitidis Serogroup B

In Ho Park,1 Ju Ho Youn,1 In-Hong Choi,1,2 Moon H. Nahm,3 Se Jong Kim,1,2 and Jeon-Soo Shin1,2*

Department of Microbiology, Brain Korea 21 Project for Medical Science,1 Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul 120-752, Korea,2 Department of Pathology, University of Alabama at Birmingham, Birmingham Alabama 35249-73313

Received 18 January 2005/ Returned for modification 2 March 2005/ Accepted 31 May 2005

Sepsis and meningitis caused by Neisseria meningitidis serogroup B (NMGB) are serious diseases in infants and young adults, but no effective vaccine is available. The capsular polysaccharide (PS) of NMGB has poor immunogenicity and a structural similarity to polysialic acid (PSA) on neuronal tissue that may elicit autoantibodies. Using HmenB3, a protective and nonautoreactive monoclonal antibody (MAb) to NMGB capsular PS, we produced an anti-idiotypic MAb, Naid60, which mimics the capsular PS of NMGB. We produced an anti-anti-idiotypic MAb, MoB34, by using the immunogenic site on Naid60 responsible for inducing the anti-NMGB PS antibody response. MoB34 elicited the complement-mediated killing of representative strains of serogroup B meningococci. MoB34 did not bind to CHP-134, a neuroblastoma cell line expressing {alpha}(2-8) PSA, or to mouse brain cryosections at a high concentration. Naid60-keyhole limpet hemocyanin immunization inhibited the growth of live NMGB in intraperitoneally challenged mice; in contrast, three of five control mice developed bacteremia. Thus, Naid60 has an immunogenic site that elicits antibodies with bactericidal activity against NMGB and no autoimmunity to PSA. We suggest that the immunogenic region of Naid60 is a candidate for the development of a new vaccine against NMGB.

* Corresponding author. Mailing address: Department of Microbiology, Yonsei University College of Medicine, 134 Shinchon-dong Seodaemoon-gu, Seoul 120-752, South Korea. Phone: 82-2-2228-1816. Fax: 82-2-392-7088. E-mail: jsshin6203{at}yumc.yonsei.ac.kr.

Editor: J. D. Clements

Infection and Immunity, October 2005, p. 6399-6406, Vol. 73, No. 10
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.10.6399-6406.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Lo Passo, C., Romeo, A., Pernice, I., Donato, P., Midiri, A., Mancuso, G., Arigo, M., Biondo, C., Galbo, R., Papasergi, S., Felici, F., Teti, G., Beninati, C. (2007). Peptide Mimics of the Group B Meningococcal Capsule Induce Bactericidal and Protective Antibodies after Immunization. J. Immunol. 178: 4417-4423 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»